- Home
- PSNY vs GLPG Comparison
PSNY vs GLPG Comparison
Compare PSNY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNY
- GLPG
- Stock Information
- Founded
- PSNY 2017
- GLPG 1999
- Country
- PSNY Sweden
- GLPG Belgium
- Employees
- PSNY N/A
- GLPG N/A
- Industry
- PSNY Auto Manufacturing
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- PSNY Consumer Discretionary
- GLPG Health Care
- Exchange
- PSNY Nasdaq
- GLPG Nasdaq
- Market Cap
- PSNY 2.1B
- GLPG 1.8B
- IPO Year
- PSNY N/A
- GLPG 2005
- Fundamental
- Price
- PSNY $1.07
- GLPG $26.49
- Analyst Decision
- PSNY Hold
- GLPG Sell
- Analyst Count
- PSNY 7
- GLPG 4
- Target Price
- PSNY $1.29
- GLPG $25.33
- AVG Volume (30 Days)
- PSNY 3.5M
- GLPG 389.2K
- Earning Date
- PSNY 03-06-2025
- GLPG 04-23-2025
- Dividend Yield
- PSNY N/A
- GLPG N/A
- EPS Growth
- PSNY N/A
- GLPG N/A
- EPS
- PSNY N/A
- GLPG N/A
- Revenue
- PSNY $2,046,740,000.00
- GLPG $311,493,731.00
- Revenue This Year
- PSNY N/A
- GLPG $0.08
- Revenue Next Year
- PSNY $77.28
- GLPG $0.23
- P/E Ratio
- PSNY N/A
- GLPG N/A
- Revenue Growth
- PSNY N/A
- GLPG 18.32
- 52 Week Low
- PSNY $0.61
- GLPG $22.36
- 52 Week High
- PSNY $1.94
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- PSNY 52.86
- GLPG 65.43
- Support Level
- PSNY $0.93
- GLPG $24.31
- Resistance Level
- PSNY $1.07
- GLPG $24.91
- Average True Range (ATR)
- PSNY 0.08
- GLPG 0.83
- MACD
- PSNY 0.01
- GLPG 0.27
- Stochastic Oscillator
- PSNY 95.17
- GLPG 95.59
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.